Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Verdiperstat - Biohaven Pharmaceuticals

Next Previous
X
Search
Drug Profile

Verdiperstat - Biohaven Pharmaceuticals

Alternative Names: AZD 3241; BHV-3241

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biohaven Pharmaceuticals
  • Class Antiparkinsonians; Ethers; Organic sulfur compounds; Pyrimidinones; Small molecules
  • Mechanism of Action Peroxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple system atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple system atrophy
  • Phase II/III Amyotrophic lateral sclerosis
  • Discontinued Parkinson's disease

Most Recent Events

  • 06 Dec 2022 Biohaven Pharmaceuticals and Massachusetts General Hospital complete the phase II/III HEALEY ALS Platform trial in Amyotrophic lateral sclerosis in USA (PO) (NCT04436510)
  • 03 Oct 2022 Biohaven Pharmaceuticals has been acquired by Pfizer
  • 29 Sep 2022 Efficacy and adverse events data from the phase II/III HEALEY ALS Platform Trial - Regimen B Verdiperstat in Amyotrophic Lateral Sclerosis released by Biohaven

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top